ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » New Mexico » Pulmonary Disease

Top Pulmonary Disease Prescribers in New Mexico

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
FRANKLIN MILLER M.D.

Pulmonary Disease

12,882

$629K

377
289 are 65+

11%
patients receiving schedule two controlled substances

Avg: 0%

25%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 65%

$49
Average prescription price

Avg: $152

VIJAY CHECHANI MD

Pulmonary Disease

3,827

$669K

418
354 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

58%
prescriptions for brand name drugs

Avg: 65%

$175
Average prescription price

Avg: $152

BRUCE SHAFFER M.D.

Pulmonary Disease

3,192

$488K

115
106 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

17%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 65%

$153
Average prescription price

Avg: $152

ABDERRAHMANE TEMMAR MD

Pulmonary Disease

2,575

$463K

441
377 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 65%

$180
Average prescription price

Avg: $152

RONALD BRONITSKY MD

Pulmonary Disease

2,533

$446K

403
353 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 65%

$176
Average prescription price

Avg: $152

DONALD PORTER MD

Pulmonary Disease

1,980

$514K

341
296 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

67%
prescriptions for brand name drugs

Avg: 65%

$260
Average prescription price

Avg: $152

VESTA SANDOVAL MD

Pulmonary Disease

1,855

$407K

252
212 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

78%
prescriptions for brand name drugs

Avg: 65%

$219
Average prescription price

Avg: $152

RICHARD SELIGMAN MD

Pulmonary Disease

1,772

$376K

212
161 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 65%

$212
Average prescription price

Avg: $152

STANISLAV BELYAEV MD

Pulmonary Disease

1,640

$324K

283
231 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

75%
prescriptions for brand name drugs

Avg: 65%

$197
Average prescription price

Avg: $152

DANIEL NAZON M.D.

Pulmonary Disease

1,614

$291K

315
260 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 65%

$180
Average prescription price

Avg: $152

JEFFREY DORF M.D.

Pulmonary Disease

1,224

$218K

213
182 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

71%
prescriptions for brand name drugs

Avg: 65%

$178
Average prescription price

Avg: $152

ASIF MUHAMMAD MD

Pulmonary Disease

1,143

$137K

238
175 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

56%
prescriptions for brand name drugs

Avg: 65%

$120
Average prescription price

Avg: $152

ARNEL ANTHONY BOBADILLA MD

Pulmonary Disease

1,130

$195K

219
158 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

73%
prescriptions for brand name drugs

Avg: 65%

$173
Average prescription price

Avg: $152

BRUCE MILLER MD

Pulmonary Disease

1,076

$193K

174
133 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 65%

$179
Average prescription price

Avg: $152

MATTHEW MONTOYA MD

Pulmonary Disease

1,075

$154K

204
165 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

63%
prescriptions for brand name drugs

Avg: 65%

$143
Average prescription price

Avg: $152

JAMES BRADLEY MD

Pulmonary Disease

1,009

$313K

187
141 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

81%
prescriptions for brand name drugs

Avg: 65%

$311
Average prescription price

Avg: $152

VIVIAN LEE MD

Pulmonary Disease

978

$301K

134
105 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

67%
prescriptions for brand name drugs

Avg: 65%

$307
Average prescription price

Avg: $152

ARCHIE SANCHEZ MD

Pulmonary Disease

885

$176K

149
119 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

81%
prescriptions for brand name drugs

Avg: 65%

$199
Average prescription price

Avg: $152

THOMAS KEHOE MD

Pulmonary Disease

749

$137K

196
170 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

77%
prescriptions for brand name drugs

Avg: 65%

$183
Average prescription price

Avg: $152

MIGUEL PELLERANO MD

Pulmonary Disease

736

$114K

125
111 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 65%

$155
Average prescription price

Avg: $152

KIRK HIPPENSTEEL M.D.

Pulmonary Disease

647

$194K

148
113 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

54%
prescriptions for brand name drugs

Avg: 65%

$300
Average prescription price

Avg: $152

ALAN ORELLANA M.D.

Pulmonary Disease

455

$98.9K

102
75 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 65%

$217
Average prescription price

Avg: $152

MICHELLE HARKINS MD

Pulmonary Disease

436

$52.4K

47
21 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

56%
prescriptions for brand name drugs

Avg: 65%

$120
Average prescription price

Avg: $152

CHANG-KUN CHOI D.O.

Pulmonary Disease

429

$55.4K

110
88 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

50%
prescriptions for brand name drugs

Avg: 65%

$129
Average prescription price

Avg: $152

SIVAKUMAR NAGARAJU MD

Pulmonary Disease

280

$87.4K

77
64 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

91%
prescriptions for brand name drugs

Avg: 65%

$312
Average prescription price

Avg: $152

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank